Ovarian cancer - PubMed
a day ago
- #ovarian cancer
- #EOC
- #BRCA mutations
- Epithelial ovarian cancer (EOC) includes various diseases with different origins, molecular profiles, and prognoses.
- High-grade serous ovarian cancer often originates from the fallopian tube, while other types like low-grade serous, clear cell, endometrioid, and mucinous EOCs arise from different tissues.
- No effective screening exists for EOC, leading to frequent late-stage diagnoses.
- Management involves surgery, chemotherapy (carboplatin and paclitaxel), and sometimes anti-angiogenic therapy.
- Poly(ADP-ribose) polymerase inhibitors improve outcomes in patients with defective homologous recombination DNA repair, such as BRCA1/2 mutations.
- Targeted therapies and immunotherapy for EOC are still under investigation.
- Translationally enriched clinical trials are needed to validate biomarkers for better treatment guidance.